Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.44 |
| ▸ | CSF1R | P07333 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2455549 | 0.83 | KDR (0.49) | KDREGFRBTKRET | |
| SCHEMBL2453411 | 0.82 | RET (0.69) | KDRRET | |
| SCHEMBL2453408 | 0.82 | RET (0.69) | KDRRET | |
| SCHEMBL1095638 | 0.82 | EGFR (0.56) | KDREGFRBTKFLT3TTBK1 | |
| SCHEMBL2453476 | 0.81 | RET (0.45) | KDREGFRBTKRET | |
| SCHEMBL2451247 | 0.81 | MAOB (0.48) | KDREGFRRET | |
| SCHEMBL2450638 | 0.79 | RET (0.54) | KDRRETCCNA2CDK2CCNA1 | |
| SCHEMBL2448477 | 0.79 | RET (0.65) | KDRCSF1RRETFLT3TEK | |
| SCHEMBL1095423 | 0.79 | EGFR (0.59) | EGFRBTKTTBK1TTBK2 | |
| SCHEMBL838399 | 0.76 | TRPA1 (0.47) | EGFRTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007109783-A2 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | WO | claimed |
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| WO-2007109783-A2 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | KDR 1975/4885CSF1R 1413/4885EGFR 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.